Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
about
Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical reviewEvaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor modelComplications, revision fusions, readmissions, and utilization over a 1-year period after bone morphogenetic protein use during primary cervical spine fusionsHealth care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.Statins Are Associated With Reduced Mortality in Multiple Myeloma.Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristicsOutcomes for single-level lumbar fusion: the role of bone morphogenetic protein.Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population.Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.Fracture risk in men with prostate cancer: a population-based study.Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United StatesCosts of early adjuvant radiation therapy after radical prostatectomy: a decision analysis.Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice.The relation between age and androgen deprivation therapy use among men in the Medicare population receiving radiation therapy for prostate cancerTargeting of androgen receptor in bone reveals a lack of androgen anabolic action and inhibition of osteogenesis: a model for compartment-specific androgen action in the skeleton.Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group.Natural history and correlates of hip BMD loss with aging in men of African ancestry: the Tobago Bone Health Study.Correlates of trabecular and cortical volumetric BMD in men of African ancestry.Hospitalization costs associated with hypertension as a secondary diagnosis among insured patients aged 18-64 years.The economic burden of inappropriate drug prescribing, lack of adherence and compliance, adverse drug events in older people: a systematic review.Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases.Bone health care for patients with prostate cancer receiving androgen deprivation therapy.Authentication of Algorithm to Detect Metastases in Men with Prostate Cancer Using ICD-9 Codes.How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.
P2860
Q24597422-6A784267-F0E6-4287-93FE-B524ECC41E14Q30405851-37D9801D-6F95-4086-A559-44592D11EC0EQ33587996-89731E38-6842-4E37-927D-CB2EC40882B6Q33723227-C49587C6-AD09-43AD-8A86-6C3587F17DB5Q33763924-1EAB6AB4-3587-484E-8BD2-12FE2B4A15BFQ33816591-41B24ABD-B655-4366-A8C3-753F72BB3A85Q34372567-2D07407C-BD23-4059-80D1-942FC39D1DBAQ35100092-21CF47F0-259D-4F05-BE4C-138F27A480B4Q35114920-AE1D5D12-2FC9-49F3-BB3A-952CE52DEB92Q35441390-8B0C6A99-5817-4A12-802D-7E0933421D1EQ35876254-802E35F7-7D73-47EF-9D28-11BAB2B05BAFQ35887353-FD78636C-E18E-47F4-8A3F-6887075FDBF0Q35902806-8CE55EE0-F30D-4745-9C1B-D7B429705702Q36478792-B217A211-82E8-4644-BD47-9AA0BC459711Q36665817-6E768E1D-6536-4AAD-9B8A-168601105823Q36952225-A5757EC8-05ED-48CA-BBA8-8707F86AEAD7Q37038406-9F0FE7C5-D3BD-4D5A-89CA-E833378E34BDQ37230567-EF58D553-218F-4CC0-96FF-8CD97E44BEA8Q37469359-D44C643E-855F-4305-897C-60E724F4152BQ37654702-FE70E0B5-86B1-4659-9787-59EC18CF432BQ38085227-BDA9587C-F494-4E71-B64B-ECB467E56261Q38122189-48718C26-5C69-451C-B165-95366D46D692Q38207463-46996418-E7BB-42D7-9FE3-83944CFC7AB9Q42378685-E865C2D3-CA8B-468F-A6FD-29B2D0B1ACC0Q44662154-1C970737-B47E-4451-A9E7-BD11DF76C095Q45330835-232D9BC6-2E2F-47E4-8BD2-E86D6B82D2B5Q47189119-F8F95358-A545-41F1-9106-7AB30F307B71
P2860
Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Health care cost associated wi ...... herapy and bone complications.
@en
type
label
Health care cost associated wi ...... herapy and bone complications.
@en
prefLabel
Health care cost associated wi ...... herapy and bone complications.
@en
P2093
P1476
Health care cost associated wi ...... herapy and bone complications.
@en
P2093
David Macarios
Kathleen A Foley
Mark S Litwin
Onur Baser
Stacey Long
Tracey L Krupski
P304
P356
10.1016/J.JURO.2007.05.135
P407
P433
P577
2007-08-16T00:00:00Z